Search

US-20260124338-A1 - ANTIBACTERIAL WOUND TREATMENTS WITH CLOT-PROMOTING PROPERTIES

US20260124338A1US 20260124338 A1US20260124338 A1US 20260124338A1US-20260124338-A1

Abstract

Wound dressings and methods for treating a wound are provided. The wound dressing can have an environment-facing side that includes a biocompatible material having a polymer crosslinked with an antimicrobial effective amount of a NO-donor and a wound-facing side including a biocompatible resinous matrix and an antifibrinolytic agent. The wound dressing can promote fibrin formation and rapid platelet aggregation, and has antimicrobial properties. The dressing can be applied directly to the wound.

Inventors

  • Jitendra Pant
  • Dieu Thao NGUYEN
  • Hitesh Handa

Assignees

  • UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.

Dates

Publication Date
20260507
Application Date
20260107

Claims (7)

  1. 1 . A wound dressing comprising a biocompatible material comprising a polymer and an antimicrobial effective amount of a NO-donor, wherein the NO-donor consists of S-nitroso-N-acetylpenicillamine, S-nitrosocysteamine, S-nitrosocysteine, S-nitroso-N-acetyl cysteamine, S-nitroso-N-acetyl cysteine, S-nitrosothioglycolate methyl S-nitrosothioglycolate, S-nitrosoglutathione, sodium nitroprusside, or any combination thereof.
  2. 2 . The wound dressing of claim 1 , wherein the NO-donor is S-nitroso-N-acetylpenicillamine.
  3. 3 . The wound dressing of claim 1 , wherein the polymer is selected from a synthetic polymer or a natural polymer.
  4. 4 . The wound dressing of claim 1 , wherein the wound dressing is a component of an article.
  5. 5 . The method of claim 4 , wherein the article is selected from the group consisting of an absorbent dressing, a wound filler or packing, a hydrogel or silicon sheet, a bandage, or a foam.
  6. 6 . A method for treating a burn or wound, the method comprising applying the wound dressing of claim 1 to the burn or wound.
  7. 7 . A method for reducing or preventing a bacterial infection in a wound or burn, the method comprising applying the wound dressing of claim 1 to the wound or burn.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS This application is a continuation application of U.S. Nonprovisional application Ser. No. 17/433,731, filed on Aug. 25, 2021, which is a 35 U.S.C. § 371 national stage application of PCT Application No. PCT/US2020/019701, filed Feb. 25, 2020, which claims the benefit of and priority to U.S. Provisional Application Ser. No. 62/810,634, filed on Feb. 26, 2019, the disclosure of which is incorporated herein by reference in their entireties. STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT This invention was made with government support under Grant No. AG055393 awarded by the NIH. The Government has certain rights in the invention. (37 CFR 401.14 f (4)) BACKGROUND Traumatic injuries range from automobile accidents to gunshots, shrapnel, and any injuries that require immediate attention and care. Every year, more than 5 million deaths happen globally due to trauma injuries. Uncontrollable hemorrhages and lacerations, the common aftermath of trauma, are the primary causes of deaths within the first 6 hours and 4 hours, respectively, among patients who are admitted into medical facilities. Uncontrollable hemorrhages contribute to approximately 50% of deaths in the first couple of days amongst both civilian and military soldiers. Excessive blood loss is responsible for nearly 30% of deaths after traumatic injuries. Infection is another leading cause of fatalities in trauma patients; indeed, it has become the second most common cause of death in patients who have experienced trauma more than 72 hours prior. Wounded sites that have not been properly treated are at a higher risk of infections. When the immune system concentrates on maintaining homeostasis while anti-inflammatory mediators focus on inhibiting the inflammation of the wounded area(s), the diversion of attention results in constant exposure of the wounded area to pathogens. This, therefore, impedes the process of wound healing while simultaneously increasing the immune disorder that can potentially cause multiple organ failures. Currently available wound dressings with antibiotics and silver ions are toxic to bacteria but at the same time are cytotoxic to mammalian cells, which is highly undesirable. There remains a need for wound dressings that overcome the aforementioned deficiencies. BRIEF DESCRIPTION OF THE DRAWINGS Further aspects of the present disclosure will be readily appreciated upon review of the detailed description of its various embodiments, described below, when taken in conjunction with the accompanying drawings. FIG. 1 is a schematic diagram showing an embodiment of the composition of instant clot forming and antibacterial wound dressing. FIG. 2 shows NO flux released from wound dressings containing NO donor, SNAP in a 1-hour period. FIG. 3 provides a comparison of platelet adhesion activity of the wound dressing with or without propolis, TXA, SNAP, and various combinations thereof. FIGS. 4A-4B show real time fibrin activation at different time points: (FIG. 4A) 12 mins (FIG. 4B) 60 min. FIGS. 5A-51 provide scanning electron microscopy and real-time images of fibrin networks, platelet entrapment, and clot formation. FIG. 6 shows a bacterial adhesion assay displaying up to more than 2 log reduction by an embodiment of a composition of the present disclosure with 7.5% TXA-SNAP-propolis. FIG. 7 shows WST-8 based cell viability assay showing non-cytotoxic nature of the dressing against mouse fibroblast cells showing the safety profile of the dressing. DETAILED DESCRIPTION In various aspects, the present disclosure provides for wound healing treatments and wound dressings with wound healing properties. In an embodiment, the present disclosure provides for wound dressings including a resinous matrix and an antifibrinolytic agent. In embodiments the dressing has an environment-facing side and a wound-facing side. The wound-facing side includes the resinous matrix and the antifibrinolytic agent. The environment-facing side can include a biocompatible material having a polymer crosslinked with an antimicrobial effective amount of a NO-donor. In various embodiments, the dressing promotes fibrin formation, rapid platelet aggregation, and has antimicrobial properties without being cytotoxic. Advantageously, the wound treatments and dressings described herein can promote clot formation within about about 60 min. or less, about 1 min. to 60 min., about 5 min. to 30 min., about 5 min. to 15 min. and inhibit bacteria at the wound site. The promotion of fibrin formation as used herein refers to a faster rate of fibrin formation in comparison to control dressings. Similarly, the platelet aggregation rate and bacterial inhibition is in comparison to control dressings that do not include an anti-fibrinolytic agent or the resinous matrix described herein. In various embodiments, the resinous matrix is and/or includes propolis. Advantageously, not only does propolis contribute to anti-inflammatory/antibac